08/21/01

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

of this Application:
Class 514 Subclass

Prior Application:
Examiner V. Balasubramanian
Group Art Unit 1624

Attorney's Docket No. 45990-ZAA/JPW/ADM

HOWARLE ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

August 20, 2001

SIR:	
This is a request for filing a $\frac{X}{}$ CONTINUATION	
DIVISIONAL CONTINUATION-IN-PART application unde	
X 37 C.F.R. §1.53(b) 37 C.F.R. §1.53(d), of pending pri	or application
Scriul No. 09/398,861 filed on September 20, 1999	of
Wai C. Wong, Yoon T. Jeon, T.G. Murali Dhar and Charles Gluchowski Inventor(s) IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF Title of Invention	for
IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF	
Title of Invention	
The statement to establish small entity states.	iginally as a
77 C F R. 61.9 and 1.27	tus under
is enclosed.	
X was filed in the prior application and such st is still proper and desired (37 C.F.R. §1.28(a	
3. X The filing fee is calculated as follows:	

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

		J	1		RA	RATE		FEE	
	NUMBER FILED		NUMBER EXTRA*		SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER
Total Claims	16-20	=	0	х	\$ 9	\$ 18	=	\$ 0	\$
Independent Claims	3_3	=	0	х	\$ 40	\$ 80	=	\$ 0	\$
Multiple Depende Claims Presen	ent ted:	<u> x</u>	Yes N	lo	^{\$} 135	\$ <u>.</u> 270	*	\$ 135	s
*If the difference in Col. 1 is			BASIC	FEE		\$355	\$ 710		
less than zero, enter "0" in				TOTAL FEE			\$ 490	\$	

filing an application pursuant to this section expressly abandons the parent application.

•,

Name: Wai C. Wong, et al. Serial No.: Not Yet Known

Filed: Herewith

cont.	Div
Page	2

4.	<u> </u>	The Commissioner is hereby authorized to charge payment of the following fees associated with this application or credit any overpayment to Deposit Account No. 03-3125.
		X Any additional filing fees required under 37 C.F.R. §1.16.
÷		X Any patent application processing fees under 37 C.F.R. §1.17.
d man		The issue fees set forth in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
5 <u>.</u>	X	Three copies of this sheet are enclosed.
5	<u> </u>	A check in the amount of \$ 490.00 is enclosed.
7:		Cancel claims
		Amend the specification by inserting before the first line the sentence:This is acontinuationdivision of application Serial No, filed
		Sheet(s) of informal formal drawing(s) is/ are enclosed.
10.		Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
11.		in
		is claimed under 37 U.S.C. §119.
		The certified copy of the priority application has been filed in prior application Serial No, filed
_. 12.	<u> </u>	The prior application is assigned of record to Synaptic Pharmaceutical Corporation
.13.	<u> </u>	A preliminary amendment and Information Disclosure Statement including PTO-1449 (EXHIBIT 1) are enclosed.
14.	<u> </u>	The power of attorney in the prior application is to:

John P. White (Reg. No. 28.678); Thomas F. Moran (Reg. No. 16.579); Norman H. Zivin (Reg. No. 25.385); Ivan S Kavrukov (Reg. No. 25.161); Christopher C. Dunham (Reg. No. 22.031); Robert D. Katz (Reg. No. 30.141); Peter J Phillips (Reg. No. 29.691); Richard S. Milner (Reg. No. 33.970); Albert Wai-Kit Chan (Reg. No. 36.479); Matthew B Tropper (Reg. No. 37.457); Robert T. Maldonaldo (Reg. 38.232); Mary Anne P. Tanner (Reg. No. 40.197); and Mary Catherine DiNunzio (Reg. No. 37.306)

Cont/Div./FWC Page 3 The power appears in the original papers in the prior application. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed. (c) X Address all future communications to: (May only be completed by applicant, or attorney or agent of record.) John P. White Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036__ Also enclosed Express Mail Certificate of Mailing No. dated August 20, 2001 EL525962992US T. I hereby verify that the attached papers are a true copy of prior application Serial No. 09/398,861 as originally filed on September 20, 1999 The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon. August 20, 2001 John P. White, Reg. No. 28,678 Signature Date INVENTOR (S) ASSIGNEE OF COMPLETE INTEREST X ATTORNEY OR AGENT OF RECORD ___ FILED UNDER 37 C.F.R. §1.34(a) · Address of Signator: Cooper & Dunham LLP 1185 Avenue of the Americas

Name: Wai C. Wong, et al. Serial No.: Not Yet Known

Filed: Herewith

New York, New York 10036

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Wai C. Wong, Yoon T. Jeon, T.G. Murali Applicants

Dhar and Charles Gluchowski

U.S. Serial No.:

Not Yet Known

Filed

Herewith

For

IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND

USES THEREOF

1185 Ave of the Americas New York, New York 10036

August 20, 2001

Assistant Commissioner for Patents

Washington, D.C. 20231

Attn: Box Patent Application

Sir:

EXPRESS MAIL CERTIFICATE OF MAILING FOR ABOVE-IDENTIFIED APPLICATION

"Express	Mail"	Mailing	Label	Number:	EL52596	52992US	
Date of					August 2	20, 2001	

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, Attn. Box Patent Application.

Printed Name

Respectfully submitted,

John/P.\White

Registration No. 28,678 Attorney for Applicant(s)

Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400